| Name | Title | Contact Details |
|---|
Nevro`s Senza system is the only SCS system capable of delivering HF10™ therapy and providing pain relief without paresthesia.
Vivosonic Inc. is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MCRA is the leading global full-service medical device, diagnostics, and biologics CRO and consulting advisory firm. MCRA delivers to its client`s industry experience, integrating its six business value creators: regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics to provide a dynamic, market-leading effort from innovation conception to commercialization. MCRA`s integrated application of these key value-creating initiatives provides unparalleled value for its clients. MCRA has offices in Washington, DC, Hartford, CT, New York, NY, and Tokyo, Japan and serves nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in vitro diagnostic (IVD) devices and medical device cybersecurity. MCRA places particular emphasis on its expertise working with companies in all stages of development and throughout the technology life cycle by ushering technologies from the conceptual pre-clinical stage to market approval.
MicroLight Corporation of America is a Missouri City, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
With more than a 60-year history of pioneering products to treat millions of patients, Cordis is a worldwide leader in the development and manufacturing of interventional cardiovascular technology. Cordis established a legacy of high-quality and minimally-invasive cardiovascular products; and has built a robust global footprint with operations in more than 60 countries around the world. As from August 2, 2021, Cordis is a standalone company, and is committed to investing $300 million to accelerate innovation in its broad product portfolio. Building on our storied brand, we are unleashing our potential to be a $10 billion leader bringing new technology to the market through bold action at speed.